SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.
Antibodies, Monoclonal
/ immunology
Antibodies, Monoclonal, Humanized
/ immunology
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ blood
COVID-19
/ therapy
Humans
Immunization, Passive
/ standards
In Vitro Techniques
Neutralization Tests
Plasma
/ immunology
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Viral Vaccines
/ immunology
COVID-19 Serotherapy
COVID-19
LyCoV016
REGN10987
SARS-CoV-2
convalescent plasma
etesevimab
imdevimab
immune escape
mutations
neutralizing antibody
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
23 06 2021
23 06 2021
Historique:
received:
18
05
2021
revised:
01
06
2021
accepted:
02
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
16
7
2021
Statut:
epublish
Résumé
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
Identifiants
pubmed: 34201767
pii: v13071211
doi: 10.3390/v13071211
pmc: PMC8310233
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
imdevimab
2Z3DQD2JHM
etesevimab
N7Q9NLF11I
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Références
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Elife. 2021 Oct 12;10:
pubmed: 34636722
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34002240
Clin Infect Dis. 2022 Feb 11;74(3):558-559
pubmed: 34036309
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
mBio. 2021 Aug 31;12(4):e0138621
pubmed: 34311587
Rev Med Virol. 2021 Mar;31(2):e2170
pubmed: 33350017
Commun Med (Lond). 2021 Nov 15;1:48
pubmed: 35602219
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34230972
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2
pubmed: 33789085
N Engl J Med. 2021 Aug 12;385(7):664-666
pubmed: 34233096
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Clin Infect Dis. 2022 Mar 1;74(4):734-742
pubmed: 34302458
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Biochem Biophys Res Commun. 2021 Aug 20;566:135-140
pubmed: 34119826
MAbs. 2021 Jan-Dec;13(1):1919285
pubmed: 34074219
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
NPJ Vaccines. 2022 Jan 27;7(1):14
pubmed: 35087066
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
Nat Commun. 2021 Aug 26;12(1):5135
pubmed: 34446720
EBioMedicine. 2022 Jan;75:103761
pubmed: 34929493
J Infect Dis. 2021 Oct 13;224(7):1109-1114
pubmed: 34223909
Sci Adv. 2021 Sep 03;7(36):eabj5365
pubmed: 34516917
Lancet Public Health. 2021 May;6(5):e335-e345
pubmed: 33857453
Clin Infect Dis. 2022 Jan 29;74(2):366-368
pubmed: 33961693
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Nature. 2021 Aug;596(7871):273-275
pubmed: 34111888
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Clin Infect Dis. 2021 Nov 16;73(10):1946-1947
pubmed: 33421056
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Epidemiol Infect. 2021 Aug 17;149:e239
pubmed: 34399868
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
Emerg Infect Dis. 2021 Oct;27(10):2728-2731
pubmed: 34314668
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
iScience. 2021 Sep 24;24(9):103006
pubmed: 34430803
Nat Commun. 2021 Oct 7;12(1):5868
pubmed: 34620866
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
Clin Infect Dis. 2021 Nov 16;73(10):1945-1946
pubmed: 33566076
Lancet Infect Dis. 2021 Aug;21(8):1071-1072
pubmed: 34051887
Emerg Infect Dis. 2021 May;27(5):1522-1524
pubmed: 33605869
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
EBioMedicine. 2021 Aug;70:103524
pubmed: 34391096
J Mol Biol. 2021 Sep 3;433(18):167155
pubmed: 34273397
J Infect Public Health. 2022 Feb;15(2):164-171
pubmed: 34959053
Emerg Microbes Infect. 2021 Dec;10(1):1499-1502
pubmed: 34176436
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Hum Vaccin Immunother. 2021 Sep 2;17(9):2959-2961
pubmed: 33950788
Clin Infect Dis. 2021 Dec 6;73(11):2000-2008
pubmed: 34134134
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219
pubmed: 34216472
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
Viruses. 2021 Jun 12;13(6):
pubmed: 34204754
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Sci Transl Med. 2022 Feb 09;14(631):eabj6824
pubmed: 34931886
Clin Transl Med. 2021 Dec;11(12):e644
pubmed: 34923762
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
Science. 2021 Mar 25;:
pubmed: 33766944
Lancet Microbe. 2021 Sep;2(9):e416-e418
pubmed: 34223399
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301
Allergy. 2021 Sep;76(9):2895-2998
pubmed: 33948956
Nat Med. 2021 Sep;27(9):1525-1529
pubmed: 34262158
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356